Takeda Pharmaceutical (4502) FY2026 Q3 Earnings Report

Quick View

Executive Summary

In Q3, revenue declined while profit increased, with cost management and improved net financial income supporting earnings as the most important points. Revenue was ¥34,111.8B (-3.3% YoY), Operating Income was ¥4,223.8B (+1.2% YoY), Profit Before Tax was ¥3,126.7B (+10.7% YoY), and Net Income attributable to owners of the parent was ¥2,160.8B (+2.4% YoY). Despite the decline in revenue, the operating margin improved to 12.4% from the previous year, while the expansion in financial income provided additional support at the pre-tax income level.

Factors Affecting Performance

【Revenue】Revenue was ¥34,111.8B, representing a 3.3% YoY decline. The cost of sales ratio increased slightly, while the SG&A ratio rose from 22.9% to 23.2%, indicating that top-line contraction and a relatively burdensome cost structure progressed simultaneously.

【Profit and Loss】Operating Income was ¥4,223.8B (+1.2% YoY), with a reduction in other operating expenses contributing to margin improvement. The operating margin improved to 12.4% from the previous year. Profit Before Tax was ¥3,126.7B (+10.7% YoY), growing faster than operating income, as increased financial income (¥2,060.2B) partially offset financial expenses (¥3,139.2B). However, the burden of income taxes was substantial, limiting Net Income growth to +2.4%. In conclusion, the current period featured declining revenue but higher profit.

Key Financial Indicators

【Profitability】The operating margin was 12.4%, improving from approximately 11.8% in the previous year. The net profit margin was approximately 6.3%, representing a slight increase from the previous year.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥9,669.0B, approximately 4.5 times Net Income of ¥2,162.8B, indicating strong cash backing for earnings. Although the ¥799.9B increase in inventories was a factor weighing on OCF, overall cash generation remained healthy, including the impact of non-cash expenses.【Investment Efficiency】ROE was 3.8%, while the Equity Ratio was 49.6%, improving from 48.7% in the previous year. Research and development expenses were ¥4,806.0B, or 14.1% of revenue, indicating continued investment at a high level.【Financial Soundness】Total assets were ¥154,087.7B and net assets were ¥76,440.9B, both increasing from the previous year. Interest-bearing debt (current + non-current) was approximately ¥48,533B, representing a substantial scale. Goodwill of ¥57,532.7B and intangible fixed assets of ¥35,156.3B accounted for approximately 60% of total assets, indicating a structure with a high degree of reliance on intangible assets.

Cash Flow Analysis

Operating Cash Flow was ¥9,669.0B, expanding substantially by +15.8% YoY and demonstrating cash generation well in excess of Net Income. Investing Cash Flow was -¥3,111.2B, including capital expenditures of ¥1,296.4B and investments in the acquisition of intangible assets. Financing Cash Flow was -¥4,193.3B, with dividend payments of ¥3,031.1B and share repurchases of ¥516.0B as the primary sources of outflow. Free Cash Flow (Operating Cash Flow + Investing Cash Flow) reached ¥6,557.8B, a level sufficient to cover both shareholder returns and investment. Cash and cash equivalents were ¥6,549.4B, increasing substantially from ¥3,851.1B in the previous year, while foreign exchange translation effects of ¥333.7B also boosted the cash balance.

Earnings Quality

Operating Cash Flow reached approximately 4.5 times Net Income, indicating strong cash backing for current-period earnings. In non-operating financial income and expenses, financial expenses of ¥3,139.2B exceeded financial income of ¥2,060.2B, and the resulting effective interest burden continued to weigh on EBT. On the other hand, Profit Before Tax increased +10.7% YoY, exceeding Operating Income growth of +1.2%, with improved net financial income contributing to the increase. Equity-method income and losses were -¥18.2B, a minor negative, indicating that the impact of external equity interests was limited. Although the increase in inventories (-¥799.9B in cash flow impact) was a factor, overall accrual levels remained healthy, and earnings quality is considered not to have been impaired.

Earnings Forecast and Guidance

The full-year earnings forecast calls for Revenue of ¥45,300.0B, Operating Income of ¥4,100.0B (+19.7% YoY), forecast EPS of ¥97.78, and forecast dividends of ¥200.00. Through Q3, Operating Income had reached ¥4,223.8B, already exceeding the full-year Operating Income forecast of ¥4,100.0B, which is noteworthy. Meanwhile, against the full-year Revenue forecast of ¥45,300.0B, cumulative Revenue for the three quarters was ¥34,111.8B, indicating progress at approximately the same pace as the previous year. Forecast EPS of ¥97.78 is below cumulative three-quarter EPS of ¥137.31, suggesting that the full-year forecast composition incorporates conservative factors or temporary factors.

Shareholder Returns

Dividends were disclosed as ¥98 per share for the interim period and forecast ¥98 per share for the year-end (¥200 for the full-year forecast), while dividend payments during the period were ¥3,031.1B. Share repurchases of ¥516.0B were conducted, bringing total shareholder returns, including dividends and share repurchases, to ¥3,547.1B. The Payout Ratio against Net Income of ¥2,162.8B was high, while the Total Return Ratio including dividends and share repurchases was even higher. Meanwhile, Operating Cash Flow of ¥9,669.0B and Free Cash Flow of ¥6,557.8B exceeded total returns, ensuring the sustainability of shareholder returns from a cash flow perspective.

Risk Factors

1. Financial expense burden: Financial expenses of ¥3,139.2B exceeded financial income of ¥2,060.2B, with the ¥1,079.0B difference weighing on EBT. Interest-bearing debt totaled approximately ¥48,533B on a current and non-current basis, resulting in high sensitivity to changes in the interest rate environment.

2. Scale of intangible assets and goodwill: Goodwill of ¥57,532.7B and intangible fixed assets of ¥35,156.3B accounted for approximately 60% of total assets of ¥154,087.7B. If the outlook for future profitability deteriorates, impairment risk may materialize.

3. Top-line contraction: Revenue declined 3.3% YoY, and with the SG&A ratio rising to 23.2%, a delayed recovery toward revenue growth could create a risk of operating leverage reversing adversely.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (pharma)

Profitability and Returns

The company maintains profitability significantly above the industry median and holds a favorable position within the industry.

Growth and Capital Efficiency

The revenue growth rate exceeds the industry median but does not reach the upper bound of the IQR (+11.2%), placing the company in the middle of the industry.

Source: Company analysis

Key Points from the Earnings Results

1. Operating Income increased despite declining revenue, and the operating margin improved from the previous year. This confirms that partial improvements in the cost structure supported the profit margin.

2. Operating Cash Flow reached approximately 4.5 times Net Income, while Free Cash Flow reached ¥6,557.8B, demonstrating cash generation sufficient to simultaneously fund dividends, share repurchases, and capital expenditures.

3. Goodwill and intangible fixed assets account for approximately 60% of total assets. Future impairment trends and the results of research and development investment (14.1% of revenue) will be key areas of focus over the medium term.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,892–¥4,109 at ±1% for the cost of equity, and ¥3,971–¥4,015 at ±0.1 for ω.

Notes:

• Since Net Income progress against the full-year forecast (140%) exceeds the standard level (75%), forecast EPS has been adjusted upward within the upper limit of +10% (because companies whose progress is ahead of schedule tend to exceed their forecasts. Adjustments may be excessive for businesses with strong seasonality).
• Net Income is substantially compressed relative to Operating Income due to the tax burden, acquisition-related expenses, and non-controlling interests (Net Income ÷ Operating Income: 38%). This figure reflects that compression at face value; if these factors are temporary, the underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
• Goodwill represents a high proportion of net assets, and the assumptions would change significantly if impairment were to occur.
• Net assets as of the quarter-end are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---